Studies have shown that CD226 is an important activating receptor in the context of NK cell-mediated tumor cell elimination. Antibody blockade of CD226 was able to inhibit human NK cells from killing hematopoietic and non-hematopoietic tumor targets. Data also have suggested that CD226 ligand expression is often up-regulated in cellular stress responses. Learn more: Next-IO™ Anti-CD226 Therapeutic Monoclonal Antibody Program